Literature DB >> 24035921

Effects of selective and non-selective inhibitors of nitric oxide synthase on morphine- and endomorphin-1-induced analgesia in acute and neuropathic pain in rats.

Wioletta Makuch1, Joanna Mika1, Ewelina Rojewska1, Magdalena Zychowska1, Barbara Przewlocka2.   

Abstract

Nitric oxide (NO) has been reported to be involved in the mechanisms of pain generation throughout the nervous system. We examined the effects of intrathecally (i.t.) administered nitric oxide synthase (NOS) inhibitors on the antinociceptive effects of morphine and endomorphin-1 during acute pain and in chronic constriction injury (CCI)-exposed rats. We used N(G)-nitro-l-arginine methyl ester (l-NAME), a non-selective NOS inhibitor; 7-nitroindazole (7-NI) or 1-(2-trifluoromethyl-phenyl)-imidazole (TRIM), selective inhibitors of neuronal NOS (NOS1); and 1400W dihydrochloride, a selective inhibitor of inducible NOS (NOS2). Morphine (0.5-2.5 μg) and endomorphin-1 (2.5-20 μg) in acute pain and morphine (10-40 μg) and endomorphin-1 (5-20 μg) after CCI-injury were combined with NOS inhibitors. For acute pain, the ED50 for endomorphin-1 (7.1 μg) was higher than that of morphine (1.3 μg) in the tail-flick test. For neuropathic pain, the ED50 value for morphine was much higher (43.2 μg) than that of endomorphin-1 (9.2 μg) in von Frey test. NOS inhibitors slightly influenced pain thresholds in both pain models. Moreover, in neuropathic pain, the effects of morphine were more potentiated by L-NAME, TRIM, 7-NI and 1400W (12×, 8.6×, 4.1× and 5.3×, respectively) than were the effects of endomorphin-1 (2.7×, 4.3×, 3.4× and 2.1×, respectively) in the von Frey test. Minocycline which is known to enhance the efficiency of morphine in neuropathic pain, decreased the mRNA expression of NOS1 in the DRG and NOS2 and C1q in the spinal cord after CCI. Both NOS2 and IBA-1 protein levels in the spinal cord and NOS1, NOS2 and IBA1 protein levels in DRG decreased after minocycline administration. In conclusion, our results provide evidence that both neuronal and non-neuronal NOS/NO pathways contribute to the behavioural pain responses evoked by nerve injury. The NOS inhibitors regardless of the type of pain enhanced morphine antinociception and, to a lesser extent, altered the effects of endomorphin-1, an opioid ligand with a peptidergic structure.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  % MPE; 1-(2-Trifluoromethyl-phenyl)-imidazole; 1400W; 7-NI; 7-Nitroindazole; CCI; DRG; EM-1; M; Mechanical allodynia; N-([3-(Aminomethyl)phenyl]methyl)ethanimidamide dihydrochloride (1400W dihydrochloride); NG-nitro-l-arginine methyl ester; NO; NOS; Neuropathic pain; Nitric oxide; Nitric oxide synthase; Nociception; TRIM; Thermal hyperalgesia; cGMP; chronic constriction injury; cyclic guanosine monophosphate; dorsal root ganglia; endomorphin-1; i.t.; intrathecal; l-NAME; morphine; nitric oxide; nitric oxide synthase; percentage of maximal possible antinociceptive effect

Mesh:

Substances:

Year:  2013        PMID: 24035921     DOI: 10.1016/j.neuropharm.2013.08.031

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  31 in total

1.  Fentanyl effects on breath generation in C57BL/6J and A/J mouse strains.

Authors:  Linnea Fechtner; Mazen El Ali; Abdus Sattar; Michael Moore; Kingman P Strohl
Journal:  Respir Physiol Neurobiol       Date:  2015-04-30       Impact factor: 1.931

Review 2.  Neuropsychiatric Effects of Antimicrobial Agents.

Authors:  Nicholas Zareifopoulos; George Panayiotakopoulos
Journal:  Clin Drug Investig       Date:  2017-05       Impact factor: 2.859

3.  Carbon Monoxide-Releasing Molecule-2 Inhibits Connexin 43-Hemichannel Activity in Spinal Cord Astrocytes to Attenuate Neuropathic Pain.

Authors:  Hui Wang; Xuejun Sun
Journal:  J Mol Neurosci       Date:  2017-08-06       Impact factor: 3.444

Review 4.  Glial source of nitric oxide in epileptogenesis: A target for disease modification in epilepsy.

Authors:  Shaunik Sharma; Sreekanth Puttachary; Thimmasettappa Thippeswamy
Journal:  J Neurosci Res       Date:  2017-12-12       Impact factor: 4.164

5.  The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway.

Authors:  Zifeng Xu; Bin Yang; Jianhai Zhang; Jijian Zheng
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

6.  The blockade of CC chemokine receptor type 1 influences the level of nociceptive factors and enhances opioid analgesic potency in a rat model of neuropathic pain.

Authors:  Katarzyna Pawlik; Anna Piotrowska; Klaudia Kwiatkowski; Katarzyna Ciapała; Katarzyna Popiolek-Barczyk; Wioletta Makuch; Joanna Mika
Journal:  Immunology       Date:  2020-02-05       Impact factor: 7.397

7.  Melatonin Suppresses Neuropathic Pain via MT2-Dependent and -Independent Pathways in Dorsal Root Ganglia Neurons of Mice.

Authors:  Jia-Ji Lin; Ye Lin; Tian-Zhi Zhao; Chun-Kui Zhang; Ting Zhang; Xiao-Li Chen; Jia-Qi Ding; Ting Chang; Zhuo Zhang; Chao Sun; Dai-Di Zhao; Jun-Lin Zhu; Zhu-Yi Li; Jin-Lian Li
Journal:  Theranostics       Date:  2017-05-12       Impact factor: 11.556

8.  A novel carboline derivative inhibits nitric oxide formation in macrophages independent of effects on tumor necrosis factor α and interleukin-1β expression.

Authors:  Ana Cristina G Grodzki; Bhaskar Poola; Nagarekha Pasupuleti; Michael H Nantz; Pamela J Lein; Fredric Gorin
Journal:  J Pharmacol Exp Ther       Date:  2014-12-23       Impact factor: 4.030

9.  The analgesic effect of apelin-13 and its mechanism of action within the nitric oxide and serotonin pathways.

Authors:  M G Turtay; M Karabas; H Parlakpinar; C Colak; M Sagir
Journal:  Hippokratia       Date:  2015 Oct-Dec       Impact factor: 0.471

10.  The nitroxyl donor, Angeli's salt, reduces chronic constriction injury-induced neuropathic pain.

Authors:  Daniela T Longhi-Balbinot; Ana C Rossaneis; Felipe A Pinho-Ribeiro; Mariana M Bertozzi; Fernando Q Cunha; José C Alves-Filho; Thiago M Cunha; Jean P S Peron; Katrina M Miranda; Rubia Casagrande; Waldiceu A Verri
Journal:  Chem Biol Interact       Date:  2016-06-07       Impact factor: 5.192

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.